Cell therapies for acute and chronic traumatic brain injury.
Acute
cell therapies
chronic
long-term disabilities
stem cells
traumatic brain injury
Journal
Current medical research and opinion
ISSN: 1473-4877
Titre abrégé: Curr Med Res Opin
Pays: England
ID NLM: 0351014
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
1
11
2022
medline:
27
12
2022
entrez:
31
10
2022
Statut:
ppublish
Résumé
Traumatic brain injury (TBI) is a global health problem, for which there are no approved therapies. Advances in acute clinical care have improved post-TBI survival, yet many patients are left with chronic TBI-related disabilities (i.e. chronic TBI). Existing treatments that focus on rehabilitation and symptom management do not modify the disease and have limited effectiveness. Consequently, chronic TBI-related disabilities remain a significant unmet medical need. Cell therapies have neuroprotective and neurorestorative effects which are believed to modify the disease. In this article, we review the safety and efficacy of cell therapies in early-phase clinical studies that have shown potential to improve outcomes in acute to chronic phases of TBI.
Identifiants
pubmed: 36314422
doi: 10.1080/03007995.2022.2141482
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM